Cullinan Therapeutics, Inc.

NASDAQ:CGEM

Medical - Pharmaceuticals

Healthcare
$9.01 +4.29%

+$0.62 today

Market cap
$584.94M
Beta
0.01
P/E (TTM)
-4.0
EPS (TTM)
-$3.73
52W Low $5.68High $16.74

Volume 1.06M

Average 0.99M

Income Statement

Follow revenue through to earnings.

Revenue

$0.00

FY 2025 · Annual

Operating Income

-$241.65M

FY 2025 · Annual

Net Income

-$219.88M

FY 2025 · Annual

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue18.94M0000
Cost of Revenue000306K0
Gross Profit18.94M00(306K)0
Gross Margin100.0%————
Research & Development57.75M91.95M148.16M142.9M187.4M
Selling, General & Admin29.15M40.19M42.49M53.71M54.25M
Operating Expenses86.9M(144.65M)191.09M196.61M241.65M
Depreciation & Amortization53K93K310K306K311K
EBITDA(67.43M)(132.04M)(190.34M)(167.15M)(219.57M)
EBITDA Margin-356.0%————
Operating Income(67.95M)144.65M(191.09M)(196.92M)(241.65M)
Operating Margin-358.7%————
Interest Income477K6.61M21.63M29.66M22.21M
Interest Expense00000
Other Income / Expenses469K6.67M21.87M29.46M21.77M
Income Before Tax(67.49M)151.32M(169.22M)(167.46M)(219.88M)
Pre-Tax Margin-356.3%————
Income Tax Expense042.12M(14.12M)117K0
Net Income(65.57M)111.21M(153.16M)(167.38M)(219.88M)
Net Margin-346.1%————
EPS (Basic)(1.48)2.46(3.69)(3.11)(3.72)
EPS (Diluted)(1.48)2.38(3.69)(3.11)(3.72)
Weighted Avg Shares44.29M45.16M41.51M53.77M59.05M
Weighted Avg Shares (Diluted)44.29M46.64M41.55M53.77M59.05M

CGEM Earnings Waterfall · TTM

NASDAQ:CGEM · Revenue to Net Income

Key Ratios

EPS$-3.75
Gross Margin0.0%
Net Margin0.0%
P/E Ratio-2.6
P/S Ratio0.0

Analysis

$0 of revenue converted into -$221.0M of net income for the selected period. Gross margin is 0.0% and net margin is 0.0%, showing how much revenue survives after costs and taxes. EPS is $-3.75, tying the income statement back to per-share earnings.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
SC 13GSC 13G filingNov 10, 2026
10-QQuarterly reportNov 10, 2026
8-KCurrent reportNov 10, 2026
8-KCurrent reportNov 9, 2026
4Statement of changes in beneficial ownershipNov 6, 2026

How much revenue does CGEM generate?

Cullinan Therapeutics, Inc. (CGEM) reported $0.00 of revenue in fiscal 2025.

Is CGEM profitable?

Cullinan Therapeutics, Inc. (CGEM) reported -$219.88M of net income.